Beam Therapeutics Reports Pipeline Updates and First Quarter

Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation Application Cleared for the Phase...

Related Keywords

United Kingdom , Cambridge , Cambridgeshire , Dan Budwick , John Evans , Holly Manning , Beam Therapeutics Inc , Nasdaq , Healthcare Products Regulatory Agency , Strategic Communications , Research Development Rd Expenses , Exchange Commission , Dosing Completed , Sentinel Cohort , Severe Sickle Cell Disease , Expansion Cohort , Trial Authorisation , Application Cleared , First Half , New Drug , First Quarter , Cash Equivalents , Marketable Securities , Cash Runway Expected , Support Operating Plans , Engineered Stem Cell Antibody Paired Evasion , Private Securities Litigation Reform Act , Annual Report , Consolidated Balance Sheet Data , Consolidated Statement , Months Ended March , Markets ,